Drugs / Alferon LDO
Alferon LDO
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00215852 Comparator | Jul 2005 → Apr 2009 | HIV infectious disease | AIM ImmunoTech Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alferon LDO | “A Randomized, Dose-Ranging Study of Alferon® LDO [Low Dose Interferon Alfa-n3 (Human Leukocyte Derived)] in Asymptomatic HIV+ Subjects” NCT00215852 ↗ |
| Known as | Low Dose Interferon Alfa-n3 (Human Leukocyte Derived) | “A Randomized, Dose-Ranging Study of Alferon® LDO [Low Dose Interferon Alfa-n3 (Human Leukocyte Derived)] in Asymptomatic HIV+ Subjects” NCT00215852 ↗ |
| Known as | natural interferon alfa-n3 | “The Alferon LDO (natural interferon alfa-n3) will be in a buffer solution and taken orally once each day for 10 consecutive days at doses equal to 500 IU, 1000 IU, or 2000 IU.” NCT00215852 ↗ |
| Modality | Protein / enzyme biologic | “Low Dose Interferon Alfa-n3 (Human Leukocyte Derived)” NCT00215852 ↗ |
| Route | Oral | “taken orally once each day” NCT00215852 ↗ |